- Brazil
- /
- Healthcare Services
- /
- BOVESPA:MATD3
Hospital Mater Dei Full Year 2024 Earnings: Revenues Miss Expectations
Hospital Mater Dei (BVMF:MATD3) Full Year 2024 Results
Key Financial Results
- Revenue: R$2.23b (up 1.8% from FY 2023).
- Net loss: R$338.4m (down by 383% from R$119.7m profit in FY 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Hospital Mater Dei Revenues Disappoint
Revenue missed analyst estimates by 2.1%.
Looking ahead, revenue is forecast to grow 7.0% p.a. on average during the next 3 years, compared to a 9.5% growth forecast for the Healthcare industry in Brazil.
Performance of the Brazilian Healthcare industry.
The company's shares are down 7.9% from a week ago.
Risk Analysis
You should learn about the 2 warning signs we've spotted with Hospital Mater Dei (including 1 which shouldn't be ignored).
Valuation is complex, but we're here to simplify it.
Discover if Hospital Mater Dei might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About BOVESPA:MATD3
Fair value with moderate growth potential.
Market Insights
Community Narratives
